Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
7.08 (1y: -33%)
Market Cap 1.08 B P/E(ttm)
Enterprise Value 1.12 B P/B 1.60
AMRN- NAS (USA)
Amarin Corporation PLC
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$7.08
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyÂ’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry		 vs
history
Cash to Debt No Debt
AMRN's Cash to Debt is ranked higher than
100% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.36 vs. AMRN: No Debt )
AMRN' s 10-Year Cash to Debt Range
Min: 0.07   Max: No Debt
Current: No Debt
Equity to Asset 0.592
AMRN's Equity to Asset is ranked higher than
100% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.52 vs. AMRN: 0.592 )
AMRN' s 10-Year Equity to Asset Range
Min: -1.06   Max: 0.81
Current: 0.59
-1.06
0.81
Interest Coverage No Debt
AMRN's Interest Coverage is ranked higher than
100% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10000.00 vs. AMRN: No Debt )
AMRN' s 10-Year Interest Coverage Range
Min: 46   Max: No Debt
Current: No Debt
F-Score: 1
Z-Score: -2.2
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyÂ’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry		 vs
history
Operating margin (%) -6232.20
AMRN's Operating margin (%) is ranked higher than
100% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.70 vs. AMRN: -6232.20 )
AMRN' s 10-Year Operating margin (%) Range
Min: -6232.2   Max: 15.8
Current: -6232.2
-6232.2
15.8
Net-margin (%) -5384
AMRN's Net-margin (%) is ranked higher than
100% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.20 vs. AMRN: -5384 )
AMRN' s 10-Year Net-margin (%) Range
Min: -5384   Max: 394.5
Current: -5384
-5384
394.5
ROE (%) -71.2
AMRN's ROE (%) is ranked higher than
100% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.20 vs. AMRN: -71.2 )
AMRN' s 10-Year ROE (%) Range
Min: -71.2   Max: 35.9
Current: -71.2
-71.2
35.9
ROA (%) -55.1
AMRN's ROA (%) is ranked higher than
100% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.00 vs. AMRN: -55.1 )
AMRN' s 10-Year ROA (%) Range
Min: -174.5   Max: 16.9
Current: -55.1
-174.5
16.9
Revenue Growth (%) -65.6
AMRN's Revenue Growth (%) is ranked higher than
100% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.20 vs. AMRN: -65.6 )
AMRN' s 10-Year Revenue Growth (%) Range
Min: -80.1   Max: 75
Current: -65.6
-80.1
75
EBITDA Growth (%) -36.2
AMRN's EBITDA Growth (%) is ranked higher than
100% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.35 vs. AMRN: -36.2 )
AMRN' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 385.9
Current: -36.2
0
385.9
EPS Growth (%) -26.6
AMRN's EPS Growth (%) is ranked higher than
100% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.20 vs. AMRN: -26.6 )
AMRN' s 10-Year EPS Growth (%) Range
Min: -67.7   Max: -11.7
Current: -26.6
-67.7
-11.7
» AMRN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

AMRN Guru Trades in Q2 2012

RS Investment Management 341,600 sh (New)
George Soros 300,000 sh (New)
Louis Moore Bacon 400,000 sh (+45.45%)
Pioneer Investments 2,411,386 sh (+18.35%)
Steven Cohen 5,806,483 sh (+1.63%)
» More
Q3 2012

AMRN Guru Trades in Q3 2012

RS Investment Management 557,845 sh (+63.3%)
Pioneer Investments 2,674,989 sh (+10.93%)
George Soros Sold Out
Steven Cohen 1,041,400 sh (-82.06%)
Louis Moore Bacon 25,000 sh (-93.75%)
» More
Q4 2012

AMRN Guru Trades in Q4 2012

John Burbank 250,000 sh (New)
Louis Moore Bacon 350,000 sh (+1300%)
RS Investment Management Sold Out
Steven Cohen 969,117 sh (-6.94%)
Pioneer Investments 1,552,770 sh (-41.95%)
» More
Q1 2013

AMRN Guru Trades in Q1 2013

Louis Moore Bacon 650,000 sh (+85.71%)
John Burbank Sold Out
Pioneer Investments 1,410,000 sh (-9.19%)
Steven Cohen 500,000 sh (-48.41%)
» More
» Details

Insider Trades

Latest Guru Trades with AMRN

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Burbank 2013-03-31 Sold Out 0.08%$6.965 - $9.16 $ 7.05-15%0
John Burbank 2012-12-31 New Buy0.08%$7.68 - $12.6 $ 7.05-35%250000
George Soros 2012-09-30 Sold Out 0.06%$11.17 - $15.49 $ 7.05-48%0
George Soros 2012-06-30 New Buy0.06%$9.47 - $14.74 $ 7.05-38%300000
George Soros 2011-09-30 Sold Out 0.058%$8.95 - $14.82 $ 7.05-41%0
George Soros 2011-06-30 Reduce -56.15%0.04%$7.39 - $19.5 $ 7.05-53%285000
George Soros 2011-03-31 Reduce -42.66%0.04%$7.03 - $9.33 $ 7.05-13%650000
George Soros 2010-12-31 New Buy0.12%$2.49 - $8.49 $ 7.0557%1133500
Premium More recent guru trades are included for Premium Members only!!

Ratios

vs
industry		 vs
history
P/B 1.60
AMRN's P/B is ranked higher than
100% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. AMRN: 1.60 )
AMRN' s 10-Year P/B Range
Min: 0.14   Max: 326.92
Current: 1.6
0.14
326.92
P/S 452.10
AMRN's P/S is ranked higher than
100% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.32 vs. AMRN: 452.10 )
AMRN' s 10-Year P/S Range
Min: 0.22   Max: 675
Current: 452.1
0.22
675
EV-to-EBIT 27
AMRN's EV-to-EBIT is ranked higher than
100% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.70 vs. AMRN: 27 )
AMRN' s 10-Year EV-to-EBIT Range
Min: 10.7   Max: 32.3
Current: 27
10.7
32.3

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 2.2
AMRN's Price/Net Cash is ranked higher than
100% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.70 vs. AMRN: 2.2 )
AMRN' s 10-Year Price/Net Cash Range
Min: 2.2   Max: 11.2
Current: 2.2
2.2
11.2
Price/Net Current Asset Value 12.4
AMRN's Price/Net Current Asset Value is ranked higher than
100% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.20 vs. AMRN: 12.4 )
AMRN' s 10-Year Price/Net Current Asset Value Range
Min: 7.9   Max: 457.2
Current: 12.4
7.9
457.2
Price/Tangible Book 2
AMRN's Price/Tangible Book is ranked higher than
100% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.40 vs. AMRN: 2 )
AMRN' s 10-Year Price/Tangible Book Range
Min: 1.9   Max: 25.3
Current: 2
1.9
25.3
Price/Median PS Value 1.2
AMRN's Price/Median PS Value is ranked higher than
100% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.70 vs. AMRN: 1.2 )
AMRN' s 10-Year Price/Median PS Value Range
Min: 0.1   Max: 16.5
Current: 1.2
0.1
16.5
Forward Rate of Return (Yacktman) 29.27
AMRN's Forward Rate of Return (Yacktman) is ranked higher than
100% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.82 vs. AMRN: 29.27 )
AMRN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -117.7   Max: -25.3
Current: 29.27
-117.7
-25.3

Business Description

Amarin Corporation PLC formerly Ethical Holdings plc is a public limited company incorporated under the laws of England and Wales. It is a late-stage biopharmaceutical company with expertise in lipid science focused on the treatment of cardiovascular disease. Amarin is a biopharmaceutical company with expertise in lipid science focused on the commercialization and development of therapeutics to improve cardiovascular health. On July 26, 2012, the Company received FDA approval to market and sells its lead product VascepaTM (icosapent ethyl) capsules (formerly known as AMR101) as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. Vascepa(icosapent ethyl) capsules is Amarin's first FDA approved product. Vascepa is a patented, ultra-pure omega-3 fatty acid, comprising not less than 96% EPA (icosapent ethyl) in a capsule. Triglycerides are fats in the blood. Hypertriglyceridemia refers to a condition in which patients have high levels of triglycerides in the bloodstream. The Company estimates that over 40 million adults in the United States have elevated triglyceride levels and approximately 4.0 million people in the United States have severe triglyceride levels. The potential efficacy and safety of Vascepa was studied in two Phase 3 clinical trials, the MARINE trial and the ANCHOR trial. These trials showed favorable clinical results in their respective patient populations in reducing triglyceride levels without a statistically significant increase in LDL-C levels, and in the 4 gram Vascepa ANCHOR results, with a statistically significant decrease in LDL-C levels. These trials also showed favorable results, particularly with the 4 gram dose of Vascepa, in other important lipid and inflammation biomarkers, including apolipoprotein B (Apo B), non-high-density lipoprotein cholesterol (non-HDL-C), Total-Cholesterol (TC), very low-density lipoprotein cholesterol, or (VLDL-C), lipoprotein-associated phospholipase A2 (Lp-PLA2), and high sensitivity C-reactive protein (hs-CRP). Any product development activities related to AMR101 or products that it may develop or acquire in the future will be subject to extensive regulation by various government authorities, including the FDA and comparable regulatory authorities in other countries, which regulate the design, research, clinical and non-clinical development, testing, manufacturing, storage, distribution, import, export, labeling, advertising and marketing of pharmaceutical products and devices.
Company Website
Industry: Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX
Traded in other countries:EH3A.Germany

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial